Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. BioStem Technologies's annualized net income for the quarter that ended in Sep. 2025 was $3.0 Mil. BioStem Technologies's average shareholder tangible equity for the quarter that ended in Sep. 2025 was $45.0 Mil. Therefore, BioStem Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 was 6.76%.
The historical rank and industry rank for BioStem Technologies's Return-on-Tangible-Equity or its related term are showing as below:
BSEM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -4521.7 Med: -694.37 Max: 165.76
Current: 43.47
During the past 13 years, BioStem Technologies's highest Return-on-Tangible-Equity was 165.76%. The lowest was -4,521.70%. And the median was -694.37%.
BSEM's Return-on-Tangible-Equity is ranked better than 94.58% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs BSEM: 43.47
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
BioStem Technologies Return-on-Tangible-Equity Related Terms
BioStem Technologies Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSEM vs XLO, TCRX, MNOV: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, BioStem Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Sep. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.76% mean?
BioStem Technologies (BSEM) has a Return-on-Tangible-Equity of 6.76% as of Sep. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #65 out of 1199 companies in the Biotechnology industry, placing it in the top 5.4%.
Is BioStem Technologies' Return-on-Tangible-Equity too high?
BioStem Technologies' current Return-on-Tangible-Equity is 6.76%. Based on the distribution chart, BioStem Technologies ranks #65 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Return-on-Tangible-Equity compare to XLO and TCRX?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #65 out of 1199 companies for Return-on-Tangible-Equity. This places BioStem Technologies in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current Return-on-Tangible-Equity is 6.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $141.65, compared to a current price of $3.24 — trading 97.7% below its estimated fair value. The current Return-on-Tangible-Equity is 6.76%. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Return-on-Tangible-Equity is 6.76% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioStem Technologies (BSEM) Overvalued in 2026?
Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued.
The current stock price of $3.24 is trading 97.7% below its estimated GF Value™ of $141.65.
GuruFocus considers BioStem Technologies to be Possible Value Trap.
Key valuation signals for BSEM:
Return-on-Tangible-Equity: 6.76%
GF Value™: $141.65 vs. price of $3.24 (97.7% below fair value)
No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score
Get the complete analysis for BSEM
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
